<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><p>Two hydrosoluble conjugates of 17β-estradiol (ED) and estradiol-17β-valerate (EV) with polyaspartamide polymer were prepared and characterized. ED and EV were first chemically modified and bound to poly[α,β-(<italic>N</italic>-2-hydroxyethyl-DL-aspartamide)]-poly[α,β-(<italic>N</italic>-2-aminoethyl-DL-aspartamide)] (PAHA), a hydrosoluble polyaspartamide-type copolymer bearing both hydroxyl and amino groups. ED was first converted to 17-hemisuccinate (EDS) and then bound to PAHA. In the resulting conjugate PAHA-EDS, the estradiol moiety was linked to the polymer through a 2-aminoethylhemisuccinamide spacer. On the other hand, EV was first converted to estradiol-17β-valerate-3-(benzotriazole-1-carboxylate), which readily reacted with amino groups in PAHA affording the polymer-drug conjugate PAHA-EV. In the prepared conjugate PAHA-EV, the estradiol moiety was covalently bound to the polyaspartamide backbone by carbamate linkage, through an ethylenediamine spacer. The polymer-drug conjugates were designed and prepared with the aim to increase water-solubility, bioavailability and to improve drug delivery of the lipophilic estrogen hormone.</p></abstract>

Two hydrosoluble conjugates of 17β-estradiol (ED) and estradiol-17β-valerate (EV) with polyaspartamide polymer were prepared and characterized. ED and EV were first chemically modified and bound to poly[α,β-(N-2-hydroxyethyl-DL-aspartamide)]-poly[α,β-(N-2-aminoethyl-DL-aspartamide)] (PAHA), a hydrosoluble polyaspartamide-type copolymer bearing both hydroxyl and amino groups. ED was first converted to 17-hemisuccinate (EDS) and then bound to PAHA. In the resulting conjugate PAHA-EDS, the estradiol moiety was linked to the polymer through a 2-aminoethylhemisuccinamide spacer. On the other hand, EV was first converted to estradiol-17β-valerate-3-(benzotriazole-1-carboxylate), which readily reacted with amino groups in PAHA affording the polymer-drug conjugate PAHA-EV. In the prepared conjugate PAHA-EV, the estradiol moiety was covalently bound to the polyaspartamide backbone by carbamate linkage, through an ethylenediamine spacer. The polymer-drug conjugates were designed and prepared with the aim to increase water-solubility, bioavailability and to improve drug delivery of the lipophilic estrogen hormone.

Macromolecular prodrugs. XIII. Hydrosoluble conjugates of 17β-estradiol and estradiol-17β-valerate with polyaspartamide polymer

Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb Croatia

Faculty of Science, Department of Chemistry, University of Zagreb, Zagreb, Croatia

Acta Pharmaceutica

Two hydrosoluble conjugates of 17β-estradiol (ED) and estradiol-17β-valerate (EV) with polyaspartamide polymer were prepared and characterized. ED and EV were...

Macromolecular prodrugs. XIII. Hydrosoluble conjugates of 17β-estradiol and estradiol-17β-valerate with polyaspartamide polymer

Published Online: Dec 25, 2011

Page range: 465 - 472

DOI: https://doi.org/10.2478/v10007-011-0039-x

Keywords
estradiol, poliaspartamid, poli[α, β-(-2-hidroksietil-DL-aspartamid)]-poli[α, β-(-2-aminoetil-DL-aspartamid)], polimer-lijek konjugat

This content is open access.

Macromolecular prodrugs. XIII. Hydrosoluble conjugates of 17β-estradiol and estradiol-17β-valerate with polyaspartamide polymer

Published Online: Dec 25, 2011

Page range: 465 - 472

DOI: https://doi.org/10.2478/v10007-011-0039-x

Keywordsestradiol, poliaspartamid, poli[α, β-(-2-hidroksietil-DL-aspartamid)]-poli[α, β-(-2-aminoetil-DL-aspartamid)], polimer-lijek konjugat

This content is open access.

Keywords
estradiol, poliaspartamid, poli[α, β-(-2-hidroksietil-DL-aspartamid)]-poli[α, β-(-2-aminoetil-DL-aspartamid)], polimer-lijek konjugat